Synthon 公司于1991 年創辦于荷蘭,集科研、開發和生產于一體。
兩年后該公司推出了第一個仿制藥品多巴酚丁胺,2003 年推出辛伐他汀獲熱銷。該公司在巴塞羅納和圣洛倫索擁有工廠,為歐洲市場生產40余種藥品。活性成分由捷克共和國和阿根廷生產,劑型則在西班牙配制。這些藥品在西班牙或美國包裝,整個流程都在Synthon 公司的質量控制下。
2004年Synthon 公司在美國推出了甲磺酸帕羅西汀制劑Pexeva?,用于治療抑郁癥。使用鹽酸帕羅西汀Paxil?的GlaxoSmithKline 公司對此提出了訴訟,已于12 月份裁定。Synthon 公司還獲得批準銷售抗抑郁藥fluvoxamine(LuvoxTM),但尚未上市。
2007 年,該公司宣布完全放棄在美國生產品牌藥的計劃,而將重點放在現有的仿制藥業務上。
Synthon, with headquarters in Nijmegen, the Netherlands is an international pharmaceutical company and a leader in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune diseases – particularly multiple sclerosis - and oncology. Our products are currently approved by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and – in dedicated areas – through direct sales. Synthon employs about 1,400 staff worldwide, and in 2011 it recorded a turnover of EUR 260 million.